ZA201707678B - Bacteria engineered to reduce hyperphenylalaninemia - Google Patents

Bacteria engineered to reduce hyperphenylalaninemia

Info

Publication number
ZA201707678B
ZA201707678B ZA2017/07678A ZA201707678A ZA201707678B ZA 201707678 B ZA201707678 B ZA 201707678B ZA 2017/07678 A ZA2017/07678 A ZA 2017/07678A ZA 201707678 A ZA201707678 A ZA 201707678A ZA 201707678 B ZA201707678 B ZA 201707678B
Authority
ZA
South Africa
Prior art keywords
bacteria engineered
hyperphenylalaninemia
reduce
reduce hyperphenylalaninemia
engineered
Prior art date
Application number
ZA2017/07678A
Other languages
English (en)
Inventor
Falb Dean
M Isabella Vincent
W Kotula Jonathan
F Miller Paul
Rowe Sarah
Millet Yves
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of ZA201707678B publication Critical patent/ZA201707678B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA2017/07678A 2015-05-13 2017-11-13 Bacteria engineered to reduce hyperphenylalaninemia ZA201707678B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562161137P 2015-05-13 2015-05-13
US201562256052P 2015-11-16 2015-11-16
PCT/US2016/032562 WO2016183531A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to reduce hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
ZA201707678B true ZA201707678B (en) 2021-03-31

Family

ID=56117975

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/07678A ZA201707678B (en) 2015-05-13 2017-11-13 Bacteria engineered to reduce hyperphenylalaninemia

Country Status (12)

Country Link
US (6) US10610546B2 (enExample)
EP (2) EP3882259A1 (enExample)
JP (3) JP6843768B2 (enExample)
AU (3) AU2016262569B9 (enExample)
BR (1) BR112017024384A2 (enExample)
CA (1) CA2985819A1 (enExample)
ES (1) ES2881384T3 (enExample)
IL (2) IL296538A (enExample)
PL (1) PL3294760T3 (enExample)
SG (1) SG10202003100XA (enExample)
WO (1) WO2016183531A1 (enExample)
ZA (1) ZA201707678B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US10610546B2 (en) * 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
DE112016002056T5 (de) 2015-05-06 2018-02-08 Snipr Technologies Limited Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
EP3294757B1 (en) * 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
EP3377518B1 (en) * 2015-11-16 2022-04-13 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
WO2018112194A1 (en) 2016-12-15 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11384358B2 (en) 2017-03-29 2022-07-12 President And Fellows Of Harvard College Method of regulating gene expression in a cell
WO2018191715A2 (en) * 2017-04-14 2018-10-18 Synthetic Genomics, Inc. Polypeptides with type v crispr activity and uses thereof
AU2018290278B2 (en) * 2017-06-21 2022-12-15 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
JP7003232B2 (ja) 2017-09-08 2022-02-04 ニュー ポータル リミテッド グルコース依存性の生存率を介して、細菌が固形腫瘍を特異的に標的とすることを可能にする核酸システム
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
CN107904222B (zh) * 2017-11-30 2019-10-08 江南大学 一种热稳定性提高的l-氨基酸脱氨酶突变体及其构建方法
EP3720458A4 (en) * 2017-12-05 2021-12-08 BioPlx, Inc. METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019396366A1 (en) 2018-12-10 2021-07-15 Tenza, Inc. Methods and compositions for treating hyperoxaluria
US20220047654A1 (en) * 2018-12-20 2022-02-17 University Of South Carolina Pharmabiotic treatments for metabolic disorders
KR20220003030A (ko) * 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
AU2020288624B2 (en) 2019-06-04 2025-09-25 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN114450403A (zh) * 2019-06-21 2022-05-06 银杏生物制品公司 用于在枫糖尿症(msud)的治疗中使用的酶的生物合成
CN110257291B (zh) * 2019-06-25 2021-07-23 北京大学 一株耐受镍离子毒性的无色杆菌及其应用
CN114761028A (zh) 2019-09-27 2022-07-15 英特瑞克斯顿阿克图比奥帝克斯有限公司 乳糜泻的治疗
EP4058578A2 (en) 2019-11-12 2022-09-21 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
KR20220130719A (ko) 2020-01-17 2022-09-27 위니베르시트카솔리끄드루뱅 엔벨로프 완전성이 변화된 유전자 변형 세균 및 이의 용도
WO2021173808A1 (en) * 2020-02-25 2021-09-02 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
BR112022018571A2 (pt) 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
CA3188581A1 (en) * 2020-07-02 2022-01-06 The Regents Of The University Of California Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
WO2022006748A1 (en) 2020-07-07 2022-01-13 New Portal Limited Genetically engineered live bacteria and methods of constructing the same
EP4196139A2 (en) 2020-08-12 2023-06-21 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
US20230332164A1 (en) * 2020-09-30 2023-10-19 Synlogic Operating Company, Inc. Bacteria engineered to secrete active proteins
EP4243834A4 (en) * 2020-11-10 2025-05-14 Palena Therapeutics, Inc. Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use
AU2021393455A1 (en) 2020-12-02 2023-06-29 Synlogic Operating Company, Inc. Engineered microorganisms
CN112501098B (zh) * 2020-12-11 2023-01-03 上海陶宇晟生物技术有限责任公司 具有降解苯丙氨酸能力的工程益生菌
CN116847860A (zh) 2020-12-31 2023-10-03 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
CN112662606A (zh) * 2021-01-06 2021-04-16 中国科学院分子植物科学卓越创新中心 用于治疗苯丙酮尿症的工程益生菌
CN112662607A (zh) * 2021-01-07 2021-04-16 上海陶宇晟生物技术有限责任公司 具备表面展示苯丙氨酸解氨酶的工程益生菌
US20240285699A1 (en) * 2021-06-24 2024-08-29 Lonza Greenwood Llc Method to Control Administration of Active Substance to the Digestive Tract
JP2024542173A (ja) 2021-11-09 2024-11-13 アクティム・セラピューティクス・インコーポレイテッド マクロファージを処置に適している表現型に変換するための免疫刺激細菌および処置のための対象の同定のためのコンパニオン診断法
CN116836899A (zh) * 2022-03-02 2023-10-03 和度生物技术(上海)有限公司 一种用于治疗高苯丙氨酸血症的工程微生物及其用途
CN114717172B (zh) * 2022-03-21 2022-09-23 江南大学 合成l-缬氨酸的大肠杆菌及其构建方法与应用
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN116463362B (zh) * 2023-06-15 2023-09-19 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法
WO2025170927A1 (en) * 2024-02-06 2025-08-14 The Cleveland Clinic Foundation Kynurenine responsive bacteria and cancer therapies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (zh) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (en) 1998-12-02 2003-03-26 Univ Boston GEN NETWORKS FOR CONTROLLING GENE EXPRESSION
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
JP4682454B2 (ja) 2000-06-28 2011-05-11 味の素株式会社 新規変異型ｎ−アセチルグルタミン酸合成酵素及びｌ−アルギニンの製造法
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
JP4347575B2 (ja) 2001-05-03 2009-10-21 アクトジェニックス・エヌブイ 自己自制ラクトコッカス（Ｌｏｃｔｏｃｏｃｃｕｓ）株
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
CA2559760A1 (en) 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
CN101068919B (zh) 2004-11-30 2011-08-10 Aeras全球Tb疫苗基金会 适用于产生和制备重组双链rna核壳的细菌包装菌株及其用途
GB0501540D0 (en) 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
CA2653967A1 (en) 2006-06-02 2008-10-02 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (zh) * 2008-05-22 2012-03-07 北京三元基因工程有限公司 一种活性乳酸乳球菌制品的制备方法
EP2344626B1 (en) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
CA3121387A1 (en) 2009-08-04 2011-02-10 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same forincreasing abiotic stress tolerance, yield, growth rate, vigor, biomass oil content, and/or nitrogen use efficiency of plants
WO2011080505A2 (en) 2009-12-28 2011-07-07 Bigdna Ltd Method of growing phage for commercial use
WO2011106874A1 (en) 2010-03-02 2011-09-09 Functional Technologies Corp. Functional enhancement of microorganisms to minimize production of acrylamide
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
US9017961B2 (en) 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
FR2990699B1 (fr) 2012-05-21 2016-02-05 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le stress
CN104487581B (zh) * 2012-06-22 2021-05-28 菲特吉恩公司 用于苯乙烯合成的酶和方法
CA2880620A1 (en) * 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
US20150246085A1 (en) * 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
CA2894710A1 (en) 2012-12-13 2014-06-19 Massachusetts Institute Of Technology Recombinase-based logic and memory systems
WO2014138324A1 (en) 2013-03-07 2014-09-12 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
SG11201508598YA (en) 2013-04-18 2015-11-27 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
BR112017011923A2 (pt) * 2014-12-05 2018-02-27 Synlogic Inc bactéria modificada para tratar doenças associadas com hiperamonemia
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US10610546B2 (en) 2015-05-13 2020-04-07 Synlogic Operating Company Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP3294757B1 (en) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
CA2987508A1 (en) 2015-05-28 2016-12-01 Evolva Sa Biosynthesis of phenylpropanoids and phenylpropanoid derivatives
EP3307870B1 (en) * 2015-06-10 2023-08-02 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (en) * 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
EP3377518B1 (en) 2015-11-16 2022-04-13 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US10982223B2 (en) 2016-06-13 2021-04-20 Benson Hill, Inc. Increasing plant growth and yield by using a phenylalanine ammonia lyase sequence
AU2018290278B2 (en) 2017-06-21 2022-12-15 Synlogic Operating Company, Inc. Bacteria for the treatment of disorders
CA3105916A1 (en) 2018-07-12 2020-01-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
BR112022018571A2 (pt) 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia
CN116847860A (zh) 2020-12-31 2023-10-03 同生运营公司 经工程化以减轻高苯丙氨酸血症的微生物
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia

Also Published As

Publication number Publication date
US10610546B2 (en) 2020-04-07
EP3294760B1 (en) 2021-03-24
ES2881384T3 (es) 2021-11-29
AU2021212141B2 (en) 2024-09-19
IL255616B (en) 2022-10-01
US12409195B2 (en) 2025-09-09
JP2023085295A (ja) 2023-06-20
IL296538A (en) 2022-11-01
CA2985819A1 (en) 2016-11-17
US20170014457A1 (en) 2017-01-19
SG10202003100XA (en) 2020-05-28
JP7245271B2 (ja) 2023-03-23
BR112017024384A2 (pt) 2018-07-24
AU2016262569B9 (en) 2021-09-16
US9943555B2 (en) 2018-04-17
AU2016262569B2 (en) 2021-05-06
US20170136073A1 (en) 2017-05-18
IL255616A (en) 2018-01-31
US10933102B2 (en) 2021-03-02
US10195234B2 (en) 2019-02-05
IL255616B2 (en) 2023-02-01
US9889164B2 (en) 2018-02-13
NZ737318A (en) 2025-03-28
JP7592777B2 (ja) 2024-12-02
PL3294760T3 (pl) 2021-11-08
JP6843768B2 (ja) 2021-03-17
US20170312320A1 (en) 2017-11-02
JP2018515106A (ja) 2018-06-14
JP2021097685A (ja) 2021-07-01
WO2016183531A1 (en) 2016-11-17
NZ775981A (en) 2025-03-28
US20200246394A1 (en) 2020-08-06
AU2021212141A1 (en) 2021-08-26
EP3882259A1 (en) 2021-09-22
US20180280451A9 (en) 2018-10-04
EP3294760A1 (en) 2018-03-21
AU2024278562A1 (en) 2025-01-09
US20160340665A1 (en) 2016-11-24
AU2016262569A1 (en) 2018-01-04
US20180169154A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
ZA201707678B (en) Bacteria engineered to reduce hyperphenylalaninemia
IL278150A (en) A transgenic bacterium for the treatment of diseases related to hyperammonemia
PL3377518T3 (pl) Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii
IL256499A (en) Antibodies to CD40
GB2541833B (en) Improvements to implant surfaces
GB201514489D0 (en) Hyperphenylalaninemia
IL256432A (en) 6-amino-quinoline-3-carbonitrils as cot modulators
GB201408039D0 (en) Culture dish
GB201409541D0 (en) Probiotic Bacteria
GB201515330D0 (en) Bioreactor condenser
GB201519450D0 (en) Novel treatment
ZA201802390B (en) Improved fermenter
GB201514420D0 (en) Bioreactor
GB201520827D0 (en) Bioreactor
GB2538045B (en) Improvements to letter-plates
GB201514734D0 (en) Mechanical bioreactor
IL256199A (en) A preparation containing a combination of peptides
GB2522473B (en) Improvements to windposts
GB201517420D0 (en) Improvements to bedpans
GB201518810D0 (en) Bioreactor
GB201517290D0 (en) Bioreactor
GB2520781B (en) Improvements to hydro-turbines
GB201521028D0 (en) Improvements to Li-fi
GB201501181D0 (en) Ready-to-assemble pond
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny